CARVYKTI (ciltacabtagene autoleucel)
Relapsed/Refractory Multiple Myeloma
Key Facts
Indication
Relapsed/Refractory Multiple Myeloma
Phase
Approved
Status
Commercial; Phase 3 trials ongoing
Company
About Legend Biotech
Legend Biotech is a leader in the development of innovative cell therapies, with a primary focus on treating hematologic malignancies and solid tumors. Its landmark achievement is the development and commercialization of CARVYKTI, a BCMA-directed CAR-T therapy approved for relapsed/refractory multiple myeloma, which it co-develops and co-commercializes with Janssen Biotech, Inc. The company leverages its integrated cell therapy platform to build a diversified pipeline, including allogeneic and armored CAR-T candidates, and maintains strategic R&D operations in the U.S., China, and Europe.
View full company profileTherapeutic Areas
Other Relapsed/Refractory Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| LB-ALLO1 | Legend Biotech | Pre-clinical |
| Cilta-cel (ciltacabtagene autoleucel) | Genscript Biotech | Approved |